Cargando…

Dosimetric Impacts of Source Migration, Radioisotope Type, and Decay with Permanent Implantable Collagen Tile Brachytherapy for Brain Tumors

Introduction: Brachytherapy using permanently implantable collagen tiles containing cesium-131 (Cs-131) is indicated for treatment of malignant intracranial neoplasms. We quantified Cs-131 source migration and modeled the resulting dosimetric impact for Cs-131, iodine-125 (I-125), and palladium-103...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinnaduwage, Dilini S., Srivastava, Shiv P., Yan, Xiangsheng, Jani, Shyam, Brachman, David G., Sorensen, Stephen P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210077/
https://www.ncbi.nlm.nih.gov/pubmed/35712977
http://dx.doi.org/10.1177/15330338221106852
_version_ 1784730082067087360
author Pinnaduwage, Dilini S.
Srivastava, Shiv P.
Yan, Xiangsheng
Jani, Shyam
Brachman, David G.
Sorensen, Stephen P.
author_facet Pinnaduwage, Dilini S.
Srivastava, Shiv P.
Yan, Xiangsheng
Jani, Shyam
Brachman, David G.
Sorensen, Stephen P.
author_sort Pinnaduwage, Dilini S.
collection PubMed
description Introduction: Brachytherapy using permanently implantable collagen tiles containing cesium-131 (Cs-131) is indicated for treatment of malignant intracranial neoplasms. We quantified Cs-131 source migration and modeled the resulting dosimetric impact for Cs-131, iodine-125 (I-125), and palladium-103 (Pd-103). Methods and Materials: This was a retrospective analysis of a subgroup of patients enrolled in a prospective, single-center, nonrandomized, clinical trial (NCT03088579) of Cs-131 collagen tile brachytherapy. Postimplant Cs-131 plans and hypothetical I-125 and Pd-103 calculations were compared for 20 glioblastoma patients for a set seed geometry. Dosimetric impact of decay and seed migration was calculated for 2 hypothetical scenarios: Scenario 1, assuming seed positions on a given image set were unchanged until acquisition of the subsequent set; Scenario 2, assuming any change in seed positions occurred the day following acquisition of the prior images. Seed migration over time was quantified for a subset of 7 patients who underwent subsequent image-guided radiotherapy. Results: Mean seed migration was 1.7 mm (range: 0.7-3.1); maximum seed migration was 4.3 mm. Mean dose to the 60 Gy volume differed by 0.4 Gy (0.6%, range 0.1-1.0) and 0.9 Gy (1.5%, range 0.2-1.7) for Cs-131, 1.2 Gy (2.0%, range 0.1-2.1) and 1.6 Gy (2.6%, range 1.2-2.6) for I-125, and 0.8 Gy (1.3%, range 0.2-1.5) and 1.4 Gy (2.3%, range 0.3-1.9) for Pd-103, for Scenarios 1 and 2, respectively, compared with the postimplant plan. For a set seed geometry mean implant dose was higher for Pd-103 (1.3 times) and I-125 (1.1 times) versus Cs-131. Dose fall-off was steepest for Pd-103: gradient index 1.88 versus 2.23 (I-125) and 2.40 (Cs-131). Conclusions: Dose differences due to source migration were relatively small, suggesting robust prevention of seed migration from Cs-131-containing collagen tiles. Intratarget heterogeneity was greater with Pd-103 and I-125 than Cs-131. Dose fall-off was fastest with Pd-103 followed by I-125 and then Cs-131.
format Online
Article
Text
id pubmed-9210077
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-92100772022-06-22 Dosimetric Impacts of Source Migration, Radioisotope Type, and Decay with Permanent Implantable Collagen Tile Brachytherapy for Brain Tumors Pinnaduwage, Dilini S. Srivastava, Shiv P. Yan, Xiangsheng Jani, Shyam Brachman, David G. Sorensen, Stephen P. Technol Cancer Res Treat Advances in Brachytherapy and Optimization of Ablative Radiotherapy Introduction: Brachytherapy using permanently implantable collagen tiles containing cesium-131 (Cs-131) is indicated for treatment of malignant intracranial neoplasms. We quantified Cs-131 source migration and modeled the resulting dosimetric impact for Cs-131, iodine-125 (I-125), and palladium-103 (Pd-103). Methods and Materials: This was a retrospective analysis of a subgroup of patients enrolled in a prospective, single-center, nonrandomized, clinical trial (NCT03088579) of Cs-131 collagen tile brachytherapy. Postimplant Cs-131 plans and hypothetical I-125 and Pd-103 calculations were compared for 20 glioblastoma patients for a set seed geometry. Dosimetric impact of decay and seed migration was calculated for 2 hypothetical scenarios: Scenario 1, assuming seed positions on a given image set were unchanged until acquisition of the subsequent set; Scenario 2, assuming any change in seed positions occurred the day following acquisition of the prior images. Seed migration over time was quantified for a subset of 7 patients who underwent subsequent image-guided radiotherapy. Results: Mean seed migration was 1.7 mm (range: 0.7-3.1); maximum seed migration was 4.3 mm. Mean dose to the 60 Gy volume differed by 0.4 Gy (0.6%, range 0.1-1.0) and 0.9 Gy (1.5%, range 0.2-1.7) for Cs-131, 1.2 Gy (2.0%, range 0.1-2.1) and 1.6 Gy (2.6%, range 1.2-2.6) for I-125, and 0.8 Gy (1.3%, range 0.2-1.5) and 1.4 Gy (2.3%, range 0.3-1.9) for Pd-103, for Scenarios 1 and 2, respectively, compared with the postimplant plan. For a set seed geometry mean implant dose was higher for Pd-103 (1.3 times) and I-125 (1.1 times) versus Cs-131. Dose fall-off was steepest for Pd-103: gradient index 1.88 versus 2.23 (I-125) and 2.40 (Cs-131). Conclusions: Dose differences due to source migration were relatively small, suggesting robust prevention of seed migration from Cs-131-containing collagen tiles. Intratarget heterogeneity was greater with Pd-103 and I-125 than Cs-131. Dose fall-off was fastest with Pd-103 followed by I-125 and then Cs-131. SAGE Publications 2022-06-17 /pmc/articles/PMC9210077/ /pubmed/35712977 http://dx.doi.org/10.1177/15330338221106852 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Advances in Brachytherapy and Optimization of Ablative Radiotherapy
Pinnaduwage, Dilini S.
Srivastava, Shiv P.
Yan, Xiangsheng
Jani, Shyam
Brachman, David G.
Sorensen, Stephen P.
Dosimetric Impacts of Source Migration, Radioisotope Type, and Decay with Permanent Implantable Collagen Tile Brachytherapy for Brain Tumors
title Dosimetric Impacts of Source Migration, Radioisotope Type, and Decay with Permanent Implantable Collagen Tile Brachytherapy for Brain Tumors
title_full Dosimetric Impacts of Source Migration, Radioisotope Type, and Decay with Permanent Implantable Collagen Tile Brachytherapy for Brain Tumors
title_fullStr Dosimetric Impacts of Source Migration, Radioisotope Type, and Decay with Permanent Implantable Collagen Tile Brachytherapy for Brain Tumors
title_full_unstemmed Dosimetric Impacts of Source Migration, Radioisotope Type, and Decay with Permanent Implantable Collagen Tile Brachytherapy for Brain Tumors
title_short Dosimetric Impacts of Source Migration, Radioisotope Type, and Decay with Permanent Implantable Collagen Tile Brachytherapy for Brain Tumors
title_sort dosimetric impacts of source migration, radioisotope type, and decay with permanent implantable collagen tile brachytherapy for brain tumors
topic Advances in Brachytherapy and Optimization of Ablative Radiotherapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210077/
https://www.ncbi.nlm.nih.gov/pubmed/35712977
http://dx.doi.org/10.1177/15330338221106852
work_keys_str_mv AT pinnaduwagedilinis dosimetricimpactsofsourcemigrationradioisotopetypeanddecaywithpermanentimplantablecollagentilebrachytherapyforbraintumors
AT srivastavashivp dosimetricimpactsofsourcemigrationradioisotopetypeanddecaywithpermanentimplantablecollagentilebrachytherapyforbraintumors
AT yanxiangsheng dosimetricimpactsofsourcemigrationradioisotopetypeanddecaywithpermanentimplantablecollagentilebrachytherapyforbraintumors
AT janishyam dosimetricimpactsofsourcemigrationradioisotopetypeanddecaywithpermanentimplantablecollagentilebrachytherapyforbraintumors
AT brachmandavidg dosimetricimpactsofsourcemigrationradioisotopetypeanddecaywithpermanentimplantablecollagentilebrachytherapyforbraintumors
AT sorensenstephenp dosimetricimpactsofsourcemigrationradioisotopetypeanddecaywithpermanentimplantablecollagentilebrachytherapyforbraintumors